Dry granulation formulation for an HIV protease inhibitor
US6645961B1 · kind B1 · utility
1Cited by
6References
19Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Mar 4, 1998 |
| Grant date | Nov 11, 2003 |
| Priority date | — |
| Expiry date | Mar 4, 2018 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K31/535
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
This invention relates to a dry granulation capsule formulation of the HIV protease inhibitor, indinavir sulfate, which is useful in the treatment of AIDS, ARC or HIV infection. Processes for making the oral formulation are also disclosed.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.